All News

Practical tips to help keep patients safe.

Savings totaled $293 billion in 2018.

Abbreviated New Drug Applications, state laws, and more.

Analysts now speculating potential next moves.

First and currently only rifabutin-based H. pylori therapy approved.

Cancer type and chemotherapy are leading risk factors.

Vaccination significantly reduces the risk of the disease.

The states pharmacists should avoid.

Why research says understanding the overlap between Kaposi sarcoma-associated herpesvirus (KSHV) and human herpesvirus 8 (HHV8)-positive large B-cell lymphomas and associated diseases may lead to better outcomes.

Site will offer CBD education and product marketing.

Walgreens and a California chain announced closures this week.

Delayed-release oral capsules for various forms of the disease.

Statin regimens may need tweaking to deliver optimal results. 

Fewer tracheobronchial branches may be a genetically-related risk factor.

Regular exercise can be an effective way to delay the onset and acceleration of COPD.

"I’ve yet to meet a pharmacist who ever had this covered in pharmacy school," writes Kreckel. 

Results presented at the 2019 NCPA Annual Convention

Governor Pritzker pushing for lighter pharmacy workloads.

Common collaborations include allergy, antibiotic, and opiate consultations.

Commercial launch suspended due to manufacturer liquidity.

What execs and experts think of the future of drug costs.

Fifth company warned about unsubstantiated claims this year.

New formulation improves safety for patients.

Approved in May 2019, granted to FoldRx, a subsidiary of Pfizer.

Previously approved for IV infusion.

Fourth indication expansion for the 2009 drug.

What to expect for these high-dollar drugs.

Drug able to treat 18,000 people will cost over $300k per year.